PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Accolade for Agilent Technologies’ Growth Strategy Leadership - Agilent Technologies, Inc. receives the 2006 Frost & Sullivan Growth Strategy Leadership Award for using research, collaboration and innovation to become a global leader in providing core bio-analytical and electronic measurement solutions
Frost & Sullivan Accolade for Agilent Technologies’ Growth Strategy Leadership

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/01/16 - Agilent Technologies, Inc. receives the 2006 Frost & Sullivan Growth Strategy Leadership Award for using research, collaboration and innovation to become a global leader in providing core bio-analytical and electronic measurement solutions.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

US based Agilent Technologies, Inc. receives the 2006 Frost & Sullivan Growth Strategy Leadership Award for using research, collaboration and innovation to become a global leader in providing core bio-analytical and electronic measurement solutions to accelerate the design, discovery and development of new products to various markets, including the life sciences industry.

“Backed by an established technology platform, Agilent offers customers a comprehensive range of application-focused solutions,” says Frost & Sullivan Programme Leader - Drug Discovery Technologies, Dr. Amarpreet Dhiman. “The company’s two segments help significantly advance critical customer needs - electronic measurement segment providing standard and customised electronic measurement instruments and systems and the bio-analytical measurement segment providing application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify, and analyse the physical and biological properties of substances and products.”

A global leader in microfluidic/lab-on-a-chip devices, the group’s cornerstone technologies utilise a network of channels and wells that are etched onto glass or polymer microarrays to build mini-laboratories. The unique technology enables sample handling, mixing, dilution, electrophoresis and chromatographic separation, staining and detection on single integrated systems.

Agilent’s flagship product– the 2100 Bioanalyzer– used for the analysis of DNA, RNA, proteins and cells, is designed to streamline RNA isolation, gene expression analysis, gene silencing, protein purification analysis, protein quality control as well as integrated cell-based parameter acquisition from as few as 20,000 cells per sample.

Equally exceptional is the HPLC-Chip/MS system, used for nanoflow electrospray LC/MS that integrates enrichment column, hydraulic connections and electrospray emitter on a single polymer chip.

Agilent Printed Microarray technology includes optimised reagents, catalogue or custom made 60-mer oligo microarrays, scanner and data analysis software. Due to its great features density, flexibility, sensitivity and powerful data analysis capabilities, this technology has extended its application range beyond whole genome gene expression analysis. New applications include oligonucleotide array-based comparative genomic hybridization (aCGH), enabling scientists to study chromosomal gains and losses relevant for cancer or other genetic diseases. Chromatin Immuno-Precipitation on chip (ChIP-on-Chip) is used to pinpoint activity at regulatory regions of chromosomes, providing insights in pathways of illness such as cancer, or cardiovascular diseases. Other emerging application areas include microarrays for methylation, alternative splicing and microRNA studies. Agilent Technologies’ printed, open-technology based microarray solutions are providing a flexible but integrated approach to successful gene expression analysis and novel, emerging, high potential applications such as copy number polymorphisms based on aCGH, ChIP-on-Chip, DNA methylation and miRNA. Agilent Technologies has continued to expand its market opportunity by designing custom microarrays with the ability to reduce cost-per-experiment by printing several microarrays on a single slide. Such technology breakthroughs, combined with strategic acquisitions like Silicon Genetics in November 2004, have resulted in integrated solutions that are playing a crucial role in advancing biomedical and life sciences research.

“With net revenues totalling over $5.1 billion in 2005 and a presence in over 110 countries, Agilent Technologies continues to successfully complement its technological edge over the industry by encompassing a range of disciplines, with the aim of capitalising on a larger marketplace,” observes Dr. Dhiman. “A cutting-edge product range, strong investment flows, judicious industrial collaborations, an exceptional IP portfolio and an innovative commercialisation strategy have given the firm the potential to expand its base of large customers, and strike more licensing deals.”

Frost & Sullivan’s Growth Strategy Leadership Award is given each year to the company that has demonstrated an exceptional growth strategy within its industry, overall and particularly for its Genomics business in Europe.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Agilent in Genomics

Agilent is a leading worldwide provider of microarray-based genomics research solutions. Agilent’s product portfolio includes reagents for sample preparation and microarray processing; systems for sample QC and high-throughput microarray scanning; 60-mer oligo microarrays, custom microarray design services; and industry-leading informatics tools including GeneSpring.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 20,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.1 billion in fiscal 2005.
About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Accolade for Agilent Technologies’ Growth Strategy Leadership

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sandra Holze 
+44 (0)20 7915 7866 sandra.holze[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)